Revolution Medicines, Inc.

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Revolution Medicines is forging ahead with plans to develop its multi-RAS inhibitor, RMC-6236, to tackle pancreatic cancer, but investor concerns about the drug’s safety in lung cancer have caused it